Nothing Special   »   [go: up one dir, main page]

LTPA2018516I1 - Testosterono kompozicijos - Google Patents

Testosterono kompozicijos

Info

Publication number
LTPA2018516I1
LTPA2018516I1 LTPA2018516C LTPA2018516C LTPA2018516I1 LT PA2018516 I1 LTPA2018516 I1 LT PA2018516I1 LT PA2018516 C LTPA2018516 C LT PA2018516C LT PA2018516 C LTPA2018516 C LT PA2018516C LT PA2018516 I1 LTPA2018516 I1 LT PA2018516I1
Authority
LT
Lithuania
Prior art keywords
testosterone compositions
testosterone
compositions
Prior art date
Application number
LTPA2018516C
Other languages
English (en)
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2018516(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of LTPA2018516I1 publication Critical patent/LTPA2018516I1/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTPA2018516C 2011-01-26 2018-10-11 Testosterono kompozicijos LTPA2018516I1 (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161436207P 2011-01-26 2011-01-26
EP11152210 2011-01-26
EP12700406.7A EP2667851B1 (en) 2011-01-26 2012-01-18 Testosterone formulations
PCT/EP2012/050695 WO2012101016A1 (en) 2011-01-26 2012-01-18 Testosterone formulations

Publications (1)

Publication Number Publication Date
LTPA2018516I1 true LTPA2018516I1 (lt) 2018-11-12

Family

ID=44146428

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP16169138.1T LT3072505T (lt) 2011-01-26 2012-01-18 Testosterono kompozicijos
LTPA2018516C LTPA2018516I1 (lt) 2011-01-26 2018-10-11 Testosterono kompozicijos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP16169138.1T LT3072505T (lt) 2011-01-26 2012-01-18 Testosterono kompozicijos

Country Status (29)

Country Link
US (2) US8895053B2 (lt)
EP (2) EP3072505B1 (lt)
JP (2) JP6012632B2 (lt)
KR (1) KR101877476B1 (lt)
CN (1) CN103327962B (lt)
AR (1) AR085090A1 (lt)
AU (1) AU2012210691B2 (lt)
BR (1) BR112013018951B1 (lt)
CA (1) CA2824941A1 (lt)
DK (2) DK3072505T3 (lt)
ES (2) ES2586122T3 (lt)
HK (1) HK1192719A1 (lt)
HR (2) HRP20160887T1 (lt)
HU (3) HUE027453T4 (lt)
IL (1) IL227454A (lt)
JO (1) JO3755B1 (lt)
LT (2) LT3072505T (lt)
MX (1) MX340259B (lt)
NO (1) NO2018034I1 (lt)
PL (2) PL2667851T3 (lt)
PT (2) PT2667851T (lt)
RS (2) RS54898B1 (lt)
RU (1) RU2613891C2 (lt)
SA (1) SA112330224B1 (lt)
SI (2) SI3072505T1 (lt)
TR (1) TR201909271T4 (lt)
TW (1) TWI564029B (lt)
WO (1) WO2012101016A1 (lt)
ZA (1) ZA201305665B (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
ES2641767T3 (es) * 2009-05-01 2017-11-13 Ferring Bv Composición para el tratamiento del cáncer de próstata
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
NZ727679A (en) 2012-06-01 2018-05-25 Ferring Bv Manufacture of degarelix
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
EP3332787A4 (en) * 2015-09-30 2018-08-01 Fujifilm Corporation Transdermally absorbable composition
US20200330371A1 (en) * 2017-10-30 2020-10-22 Teikoku Seiyaku Co., Ltd. Transdermally administrable preparation
WO2019140087A1 (en) 2018-01-10 2019-07-18 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
CN109700764B (zh) * 2019-02-20 2021-07-06 广东食品药品职业学院 双氢睾酮原位凝胶喷雾剂及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2862341D1 (en) 1977-12-26 1983-11-24 Ihara Chemical Ind Co Process for producing aromatic monocarboxylic acid
DK0593491T3 (da) 1991-04-25 1997-03-17 Romano Deghenghi Luteiniseringshormonfrigørende hormonantagonistpeptider
EP0556034B2 (en) 1992-02-12 2004-07-21 Daikyo Gomu Seiko Ltd. A medical instrument
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
CN1997357A (zh) * 2003-03-11 2007-07-11 安塔雷斯制药Ipl股份公司 透皮或透粘膜应用活性剂的用途和制剂
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2007124250A2 (en) * 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
EP1896038B1 (en) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Method and composition for testosterone transdermal delivery
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EA018775B1 (ru) * 2007-03-23 2013-10-30 Юнимед Фармасьютикалз Ллк Применение тестостерона в форме водно-спиртового геля для лечения детского гипогонадизма
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
WO2009102720A1 (en) 2008-02-11 2009-08-20 Safety Syringes, Inc. Reconstitution means for safety device
ES2641767T3 (es) 2009-05-01 2017-11-13 Ferring Bv Composición para el tratamiento del cáncer de próstata
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2012024361A1 (en) * 2010-08-17 2012-02-23 Biosante Pharmaceuticals, Inc. Commercial scale production methods for transdermal hormone formulations
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013012783A1 (en) 2011-07-15 2013-01-24 Joseph Raymond E Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
HUE027453T4 (hu) 2018-12-28
SA112330224B1 (ar) 2015-02-22
AU2012210691A1 (en) 2013-08-01
MX340259B (es) 2016-07-04
RU2613891C2 (ru) 2017-03-21
SI2667851T1 (sl) 2016-07-29
US20150110856A1 (en) 2015-04-23
JP6012632B2 (ja) 2016-10-25
AR085090A1 (es) 2013-09-11
HRP20191216T1 (hr) 2019-10-18
NO2018034I1 (no) 2018-09-27
ES2741744T3 (es) 2020-02-12
SI3072505T1 (sl) 2019-08-30
HK1192719A1 (zh) 2014-08-29
MX2013008463A (es) 2013-10-03
ES2586122T3 (es) 2016-10-11
DK3072505T3 (da) 2019-08-12
TR201909271T4 (tr) 2019-07-22
JP2017019819A (ja) 2017-01-26
DK2667851T3 (en) 2016-07-25
PL2667851T3 (pl) 2017-01-31
EP3072505B1 (en) 2019-06-12
RS54898B1 (sr) 2016-10-31
BR112013018951A2 (pt) 2017-04-04
PT3072505T (pt) 2019-07-04
HUE044327T2 (hu) 2019-10-28
IL227454A (en) 2017-02-28
JP2014503565A (ja) 2014-02-13
ZA201305665B (en) 2014-03-26
CA2824941A1 (en) 2012-08-02
AU2012210691B2 (en) 2016-05-12
PT2667851T (pt) 2016-07-26
EP3072505A1 (en) 2016-09-28
LT3072505T (lt) 2019-08-26
BR112013018951B1 (pt) 2020-03-10
PL3072505T3 (pl) 2019-12-31
CN103327962A (zh) 2013-09-25
NZ613029A (en) 2014-03-28
HUS1800036I1 (hu) 2018-09-28
TWI564029B (zh) 2017-01-01
HUE027453T2 (en) 2016-09-28
US8895053B2 (en) 2014-11-25
IL227454A0 (en) 2013-09-30
RS59012B1 (sr) 2019-08-30
WO2012101016A1 (en) 2012-08-02
HRP20160887T1 (hr) 2016-09-23
CN103327962B (zh) 2016-04-27
JO3755B1 (ar) 2021-01-31
US20130295166A1 (en) 2013-11-07
TW201309341A (zh) 2013-03-01
RU2013133082A (ru) 2015-03-10
EP2667851A1 (en) 2013-12-04
KR20140041431A (ko) 2014-04-04
EP2667851B1 (en) 2016-05-18
KR101877476B1 (ko) 2018-07-11

Similar Documents

Publication Publication Date Title
LTPA2018516I1 (lt) Testosterono kompozicijos
BR112013017183A2 (pt) composições de bepostatina
BR112013022112A2 (pt) composição
DK2640893T4 (da) Sammensætninger
BR112013022102A2 (pt) composição
DK2686017T3 (da) Oftalmisk sammensætning
CO6970594A2 (es) Composiciones hemostáticas
BR112014004395A2 (pt) composição
DK3513803T3 (da) Hæmostatiske sammensætninger
CO6930368A2 (es) Composiciones de yodo-povidona estable
BR112013033808A2 (pt) composição
GB201117619D0 (en) Compositions
GB201117621D0 (en) Compositions
EP2763756A4 (en) BROMOFLUOROCARBON COMPOSITIONS
GB2496447B (en) Compositions
BR112014007030A2 (pt) composição
BR112013031545A2 (pt) composições cosméticas
GB201110833D0 (en) Compositions
GB201103942D0 (en) Compositions
CO7010827A2 (es) Composiciones mejoradas
DK2811828T3 (da) Adjuvanssammensætninger
BR112013031357A2 (pt) composições cosméticas
BR112013000109A2 (pt) composições
GB201104849D0 (en) Compositions
DK2726579T3 (da) Sammensætning